Top

Published in:

01-12-2012 | Pain Aspects of Arthritis (DA Walsh and S Kelly, Section Editors)

Neurophysiology of Arthritis Pain

Authors: Jason J. McDougall, Patrick Linton

Published in: Current Pain and Headache Reports | Issue 6/2012

Abstract

Arthritis pain is a complex phenomenon involving intricate neurophysiological processing at all levels of the pain pathway. The treatment options available to alleviate joint pain are fairly limited and most arthritis patients report only modest pain relief with current treatments. A better understanding of the neural mechanisms responsible for musculoskeletal pain and the identification of new targets will help in the development of future pharmacological therapies. This article reviews some of the latest research into factors which contribute to joint pain and covers areas such as cannabinoids, proteinase activated receptors, sodium channels, cytokines and transient receptor potential channels. The emerging hypothesis that osteoarthritis may have a neuropathic component is also discussed.

World Health Organization. The burden of musculoskeletal conditions at the start of the new millennium. World Health Organ Tech Rep Ser. 2003;919:1–218.

McDougall JJ. Arthritis and pain. Neurogenic origin of joint pain. Arthritis Res Ther. 2006;8:220–9.PubMedCrossRef

Hannan MT, Felson DT, Pincus T. Analysis of the discordance between radiographic changes and knee pain in osteoarthritis of the knee. J Rheumatol. 2000;27:1513–17.PubMed

Lethbridge-Cejku M, Scott Jr WW, Reichle R, Ettinger WH, Zonderman A, Costa P, Plato CC, Tobin JD, Hochberg MC. Association of radiographic features of osteoarthritis of the knee with knee pain: data from the Baltimore Longitudinal Study of Aging. Arthritis Care Res. 1995;8:182–8.PubMedCrossRef

•• McDougall JJ, Andruski B, Schuelert N, Hallgrimsson B, Matyas JR. Unravelling the relationship between age, nociception and joint destruction in naturally occurring osteoarthritis of Dunkin Hartley guinea pigs. Pain. 2009;141:222–32. This study showed for the first time a lack of correlation between joint degeneration and nociception in an animal model of spontaneous OA.PubMedCrossRef

Schuelert N, McDougall JJ. Cannabinoid-mediated antinociception is enhanced in rat osteoarthritic knees. Arthritis and Rheum. 2008;58:145–53.CrossRef

Devane WA, Dysarz 3rd FA, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol. 1988;34:605–13.PubMed

Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990;346:561–4.PubMedCrossRef

Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365:61–5.PubMedCrossRef

10.

Baker CL, McDougall JJ. The cannabinomimetic arachidonyl-2-chloroethylamide (ACEA) acts on capsaicin-sensitive TRPV1 receptors but not cannabinoid receptors in rat joints. Br J Pharmacol. 2004;142:1361–7.PubMedCrossRef

11.

McDougall JJ, Yu V, Thomson J. In vivo effects of CB2 receptor-selective cannabinoids on the vasculature of normal and arthritic rat knee joints. Br J Pharmacol. 2008;153:358–66.PubMedCrossRef

12.

Schuelert N, Zhang C, Mogg AJ, Broad LM, Hepburn DL, Nisenbaum ES, Johnson MP, McDougall JJ. Paradoxical effects of the cannabinoid CB2 receptor agonist GW405833 on rat osteoarthritic knee joint pain. Osteoarthr Cartil. 2010;18:1536–43.PubMedCrossRef

13.

Carlini EA. The good and the bad effects of (-) trans-delta-9-tetrahydrocannabinol (Delta 9-THC) on humans. Toxicon. 2004;44:461–7.PubMedCrossRef

14.

Degenhardt L, Hall WD. The adverse effects of cannabinoids: implications for use of medical marijuana. CMAJ. 2008;178:1685–6.PubMedCrossRef

15.

Leweke FM, Koethe D. Cannabis and psychiatric disorders: it is not only addiction. Addict Biol. 2008;13:264–75.PubMedCrossRef

16.

Wang T, Collet JP, Shapiro S, Ware MA. Adverse effects of medical cannabinoids: a systematic review. CMAJ. 2008;178:1669–78.PubMedCrossRef

17.

Di Marzo V. Endocannabinoids: synthesis and degradation. Rev Physiol Biochem Pharmacol. 2008;160:1–24.PubMed

18.

Deutsch DG, Ueda N, Yamamoto S. The fatty acid amide hydrolase (FAAH). Prostaglandins Leukot Essent Fatty Acids. 2002;66:201–10.PubMedCrossRef

19.

• Schuelert N, Johnson MP, Oskins JL, Jassal K, Chambers MG, McDougall JJ. Local application of the endocannabinoid hydrolysis inhibitor URB597 reduces nociception in spontaneous and chemically induced models of osteoarthritis. Pain. 2011;152:975–81. This study gave the first indication that endocannabinoids could be promoted in osteoarthritic joints leading to analgesia.PubMedCrossRef

20.

Pertwee RG. GPR55: a new member of the cannabinoid receptor clan? Br J Pharmacol. 2007;152:984–6.PubMedCrossRef

21.

Lauckner JE, Jensen JB, Chen HY, Lu HC, Hille B, Mackie K. GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci U S A. 2008;105:2699–704.PubMedCrossRef

22.

Staton PC, Hatcher JP, Walker DJ, Morrison AD, Shapland EM, Hughes JP, Chong E, Mander PK, Green PJ, Billinton A, Fulleylove M, Lancaster HC, Smith JC, Bailey LT, Wise A, Brown AJ, Richardson JC, Chessell IP. The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain. Pain. 2008;139:225–36.PubMedCrossRef

23.

Ryberg E, Larsson N, Sjogren S, Hjorth S, Hermansson NO, Leonova J, Elebring T, Nilsson K, Drmota T, Greasley PJ. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol. 2007;152:1092–101.PubMedCrossRef

24.

Schuelert N, McDougall JJ. The abnormal cannabidiol analogue O-1602 reduces nociception in a rat model of acute arthritis via the putative cannabinoid receptor GPR55. Neurosci Lett. 2011;500:72–6.PubMedCrossRef

25.

Jones SA, Richards PJ, Scheller J, Rose-John S. IL-6 transsignaling: the in vivo consequences. J Interferon Cytokine Res. 2005;25:241–53.PubMedCrossRef

26.

Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta. 2011;1813:878–88.PubMedCrossRef

27.

Arvidson NG, Gudbjornsson B, Elfman L, Ryden AC, Totterman TH, Hallgren R. Circadian rhythm of serum interleukin-6 in rheumatoid arthritis. Ann Rheum Dis. 1994;53:521–4.PubMedCrossRef

28.

De Benedetti F, Massa M, Pignatti P, Albani S, Novick D, Martini A. Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis. J Clin Invest. 1994;93:2114–19.PubMedCrossRef

29.

Desgeorges A, Gabay C, Silacci P, Novick D, Roux-Lombard P, Grau G, Dayer JM, Vischer T, Guerne PA. Concentrations and origins of soluble interleukin 6 receptor-alpha in serum and synovial fluid. J Rheumatol. 1997;24:1510–16.PubMed

30.

Vazquez E, Kahlenbach J, von Segond Banchet G, Konig C, Schaible HG, Ebersberger A. Spinal interleukin-6 is an amplifier of arthritic pain in the rat. Arthritis Rheum. 2012;64:2233–42.PubMedCrossRef

31.

Keeble J, Russell F, Curtis B, Starr A, Pinter E, Brain SD. Involvement of transient receptor potential vanilloid 1 in the vascular and hyperalgesic components of joint inflammation. Arthritis Rheum. 2005;52:3248–56.PubMedCrossRef

32.

Eid SR, Crown ED, Moore EL, Liang HA, Choong KC, Dima S, Henze DA, Kane SA, Urban MO. HC-030031, a TRPA1 selective antagonist, attenuates inflammatory- and neuropathy-induced mechanical hypersensitivity. Mol Pain. 2008;4:48.PubMedCrossRef

33.

Petrus M, Peier AM, Bandell M, Hwang SW, Huynh T, Olney N, Jegla T, Patapoutian A. A role of TRPA1 in mechanical hyperalgesia is revealed by pharmacological inhibition. Mol Pain. 2007;3:40.PubMedCrossRef

34.

Fernihough J, Gentry C, Bevan S, Winter J. Regulation of calcitonin gene-related peptide and TRPV1 in a rat model of osteoarthritis. Neurosci Lett. 2005;388:75–80.PubMedCrossRef

35.

Chu KL, Chandran P, Joshi SK, Jarvis MF, Kym PR, McGaraughty S. TRPV1-related modulation of spinal neuronal activity and behavior in a rat model of osteoarthritic pain. Brain Res. 2011;1369:158–66.PubMedCrossRef

36.

Kim H, Neubert JK, San Miguel A, Xu K, Krishnaraju RK, Iadarola MJ, Goldman D, Dionne RA. Genetic influence on variability in human acute experimental pain sensitivity associated with gender, ethnicity and psychological temperament. Pain. 2004;109:488–96.PubMedCrossRef

37.

Valdes AM, De Wilde G, Doherty SA, Lories RJ, Vaughn FL, Laslett LL, Maciewicz RA, Soni A, Hart DJ, Zhang W, Muir KR, Dennison EM, Wheeler M, Leaverton P, Cooper C, Spector TD, Cicuttini FM, Chapman V, Jones G, Arden NK, Doherty M. The Ile585Val TRPV1 variant is involved in risk of painful knee osteoarthritis. Ann Rheum Dis. 2011;70:1556–61.PubMedCrossRef

38.

Fernandes ES, Russell FA, Spina D, McDougall JJ, Graepel R, Gentry C, Staniland AA, Mountford DM, Keeble JE, Malcangio M, Bevan S, Brain SD. A distinct role for transient receptor potential ankyrin 1, in addition to transient receptor potential vanilloid 1, in tumor necrosis factor alpha-induced inflammatory hyperalgesia and Freund’s complete adjuvant-induced monarthritis. Arthritis Rheum. 2011;63:819–29.PubMedCrossRef

39.

Russell FA, McDougall JJ. Proteinase activated receptor (PAR) involvement in mediating arthritis pain and inflammation. Inflamm Res. 2009;58(3):119–26.PubMedCrossRef

40.

Russell FA, Schuelert N, Veldhoen VE, Hollenberg MD, McDougall JJ. Proteinase-activated receptor-2 (PAR(2) ) activation sensitises primary afferents and causes leukocyte rolling and adherence in the rat knee joint. Br J Pharmacol. doi:10.1111/j.1476-5381.2012.02120.x.

41.

Russell FA, Veldhoen VE, Tchitchkan D, McDougall JJ. Proteinase-activated receptor-4 (PAR4) activation leads to sensitization of rat joint primary afferents via a bradykinin B2 receptor-dependent mechanism. J Neurophysiol. 2010;103:155–63.PubMedCrossRef

42.

Nakano S, Ikata T, Kinoshita I, Kanematsu J, Yasuoka S. Characteristics of the protease activity in synovial fluid from patients with rheumatoid arthritis and osteoarthritis. Clin Exp Rheumatol. 1999;17:161–70.PubMed

43.

McDougall JJ, Schuelert N, Bowyer J. Cathepsin K inhibition reduces CTXII levels and joint pain in the guinea pig model of spontaneous osteoarthritis. Osteoarthr Cartil. 2010;18:1355–7.PubMedCrossRef

44.

Helyes Z, Sandor K, Borbely E, Tekus V, Pinter E, Elekes K, Toth DM, Szolcsanyi J, McDougall JJ. Involvement of transient receptor potential vanilloid 1 receptors in protease-activated receptor-2-induced joint inflammation and nociception. Eur J Pain. 2010;14:351–8.PubMedCrossRef

45.

McDougall JJ, Zhang C, Cellars L, Joubert E, Dixon CM, Vergnolle N. Triggering of proteinase-activated receptor 4 leads to joint pain and inflammation in mice. Arthritis Rheum. 2009;60:728–37.PubMedCrossRef

46.

Russell FA, Zhan S, Dumas A, Lagarde S, Pouliot M, McDougall JJ. The pronociceptive effect of proteinase-activated receptor-4 stimulation in rat knee joints is dependent on mast cell activation. Pain. 2011;152:354–60.PubMedCrossRef

47.

Amir R, Argoff CE, Bennett GJ, Cummins TR, Durieux ME, Gerner P, Gold MS, Porreca F, Strichartz GR. The role of sodium channels in chronic inflammatory and neuropathic pain. J Pain. 2006;7(5 Suppl 3):S1–29.PubMed

48.

Akopian AN, Sivilotti L, Wood JN. A tetrodotoxin-resistant voltage-gated sodium channel expressed by sensory neurons. Nature. 1996;379:257–62.PubMedCrossRef

49.

Akopian AN, Souslova V, England S, Okuse K, Ogata N, Ure J, Smith A, Kerr BJ, McMahon SB, Boyce S, Hill R, Stanfa LC, Dickenson AH, Wood JN. The tetrodotoxin-resistant sodium channel SNS has a specialized function in pain pathways. Nat Neurosci. 1999;2:541–8.PubMedCrossRef

50.

Strickland IT, Martindale JC, Woodhams PL, Reeve AJ, Chessell IP, McQueen DS. Changes in the expression of NaV1.7, NaV1.8 and NaV1.9 in a distinct population of dorsal root ganglia innervating the rat knee joint in a model of chronic inflammatory joint pain. Eur J Pain. 2008;12:564–72.PubMedCrossRef

51.

Karaman Y, Kayali C, Ozturk H, Kaya A, Bor C. A comparison of analgesic effect of intra-articular levobupivacaine with bupivacaine following knee arthroscopy. Saudi Med J. 2009;30:629–32.PubMed

52.

Araujo MC, Sinnott CJ, Strichartz GR. Multiple phases of relief from experimental mechanical allodynia by systemic lidocaine: responses to early and late infusions. Pain. 2003;103:21–9.PubMedCrossRef

53.

Kastrup J, Petersen P, Dejgard A, Angelo HR, Hilsted J. Intravenous lidocaine infusion—a new treatment of chronic painful diabetic neuropathy? Pain. 1987;28:69–75.PubMedCrossRef

54.

Kinloch RA, Cox PJ. New targets for neuropathic pain therapeutics. Expert Opin Ther Targets. 2005;9:685–98.PubMedCrossRef

55.

Schuelert N, McDougall JJ. Involvement of Nav 1.8 sodium ion channels in the transduction of mechanical pain in a rodent model of osteoarthritis. Arthritis Res Ther. 2012;14:R5.PubMedCrossRef

56.

Jarvis MF, Honore P, Shieh CC, Chapman M, Joshi S, Zhang XF, Kort M, Carroll W, Marron B, Atkinson R, Thomas J, Liu D, Krambis M, Liu Y, McGaraughty S, Chu K, Roeloffs R, Zhong C, Mikusa JP, Hernandez G, Gauvin D, Wade C, Zhu C, Pai M, Scanio M, Shi L, Drizin I, Gregg R, Matulenko M, Hakeem A, Gross M, Johnson M, Marsh K, Wagoner PK, Sullivan JP, Faltynek CR, Krafte DS. A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat. Proc Natl Acad Sci U S A. 2007;104:8520–5.PubMedCrossRef

57.

Coggeshall RE, Tate S, Carlton SM. Differential expression of tetrodotoxin-resistant sodium channels Nav1.8 and Nav1.9 in normal and inflamed rats. Neurosci Lett. 2004;355:45–8.PubMedCrossRef

58.

McDougall JJ, Bray RC, Sharkey KA. A morphological and immunohistochemical examination of nerves in normal and injured collateral ligaments of rat, rabbit and human knee joints. Anat Rec. 1997;248:29–39.PubMedCrossRef

59.

McDougall JJ, Yeung G, Leonard CA, Bray RC. A rôle for calcitonin gene-related peptide in rabbit knee joint ligament healing. Can J Physiol Pharmacol. 2000;78:535–40.PubMedCrossRef

60.

Grönblad M, Konntinen YT, Korkala O, Liesi P, Hukkanen M, Polak JM. Neuropeptides in the synovium of patients with rheumatoid arthritis and osteoarthritis. J Rheumatol. 1988;15:1807–10.PubMed

61.

Hanesch U, McDougall JJ, Pawlak M. Inhibitory effects of gabapentin on rat articular afferent mechanosensitivity. Regul Pept. 2000;89:63.

62.

Orita S, Ishikawa T, Miyagi M, Ochiai N, Inoue G, Eguchi Y, Kamoda H, Arai G, Toyone T, Aoki Y, Kubo T, Takahashi K, Ohtori S. Pain-related sensory innervation in monoiodoacetate-induced osteoarthritis in rat knees that gradually develops neuronal injury in addition to inflammatory pain. BMC Musculoskelet Disord. 2011;12:134.PubMedCrossRef

Title: Neurophysiology of Arthritis Pain
Authors: Jason J. McDougall
Patrick Linton
Publication date: 01-12-2012
Publisher: Current Science Inc.
Published in: Current Pain and Headache Reports / Issue 6/2012
Print ISSN: 1531-3433
Electronic ISSN: 1534-3081
DOI: https://doi.org/10.1007/s11916-012-0300-0

At a glance: The STEP trials

Springer Medicine

Neurophysiology of Arthritis Pain

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2012

Neuromuscular Function in Painful Knee Osteoarthritis

Epidemiology and Cultural Differences in Tension-Type Headache

The Context of Pain in Arthritis: Self-efficacy for Managing Pain and Other Symptoms

Erratum to: Imaging Pain in Arthritis: Advances in Structural and Functional Neuroimaging

Combat-Related Headache and Traumatic Brain Injury

Complementary and Alternative Approaches to the Treatment of Tension-Type Headache